PTPRC and neoplasm: In the in vivo Lewis lung carcinoma (LLC)-tumor-bearing mice model, we showed that oral administration of phloroglucinol significantly inhibited tumor growth and angiogenesis as well as the mobilization of circulating EPCs, CD45−/CD34+ progenitor cells.